enVVeno Medical (enVVeno Medical) Total Liabilities : $2.46 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is enVVeno Medical Total Liabilities?

enVVeno Medical's Total Liabilities for the quarter that ended in Mar. 2024 was $2.46 Mil.

enVVeno Medical's quarterly Total Liabilities declined from Sep. 2023 ($3.18 Mil) to Dec. 2023 ($2.44 Mil) but then increased from Dec. 2023 ($2.44 Mil) to Mar. 2024 ($2.46 Mil).

enVVeno Medical's annual Total Liabilities declined from Dec. 2021 ($3.30 Mil) to Dec. 2022 ($2.93 Mil) and declined from Dec. 2022 ($2.93 Mil) to Dec. 2023 ($2.44 Mil).

enVVeno Medical Total Liabilities Historical Data

The historical data trend for enVVeno Medical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

enVVeno Medical Total Liabilities Chart

enVVeno Medical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2.44

3.44

3.30

2.93

2.44

enVVeno Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															2.48	3.27	3.18	2.44	2.46

enVVeno Medical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

enVVeno Medical's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.371	+	(1.064	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.44

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	48.635	-	46.2
	=	2.44

enVVeno Medical's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.487	+	(0.973	+	-1.1102230246252E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.46

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	44.829	-	42.369
	=	2.46

enVVeno Medical Total Liabilities Related Terms

Thank you for viewing the detailed overview of enVVeno Medical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

enVVeno Medical (enVVeno Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » enVVeno Medical Corp (NAS:NVNO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

5HJ:Germany 5HJ:Germany

Address

70 Doppler, Irvine, CA, USA, 92618

Website

https://www.envveno.com

enVVeno Medical Corp is a medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).

Executives

Hamed Alavi	officer: Chief Technology Officer	ENVVENO MEDICAL CORPORATION, 70 DOPPLER, IRVINE CA 92618
Francis Duhay	director	HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Sanjay Shrivastava	director	HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert Andrew Berman	director, officer: CEO	C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Matthew Jenusaitis	director	2 GOODYEAR, IRVINE CA 92618
Robert Gray	director	70 DOPPLER, IRVINE CA 92618
Marc H. Glickman	officer: See Remarks	70 DOPPLER, IRVINE CA 92618
Biodyne Holding, S.a.	10 percent owner	13 RUE DE LA GARE, MORGES V8 1110
Craig Glynn	officer: Chief Financial Officer	70 DOPPLER, IRVINE CA 92618
Marcus W. Robins	director	C/O HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert A Rankin	officer: Chief Financial Officer	9200 SUNSET BLVD., SUITE 425, WEST HOLLYWOOD CA 90069
Browston Trading Ltd	10 percent owner	P.O. BOX 20533, NICOSIA G4 1660
Robert W. Doyle	director	70 DOPPLER, IRVINE CA 92618
Robert A. Anderson	director	70 DOPPLER, IRVINE CA 92618
Susan Montoya	officer: See Remarks	70 DOPPLER, IRVINE CA 92618